H.C. Wainwright initiated coverage on Predictive Oncology with a new price target
$POAI
Industrial Specialties
Health Care
H.C. Wainwright initiated coverage of Predictive Oncology with a rating of Buy and set a new price target of $3.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/19/2024 | $3.00 | Buy | H.C. Wainwright |
| 6/30/2021 | $5.00 | Buy | HC Wainwright & Co. |
New indications discovered by applying active machine learning and using samples from the company's vast biobank of live-cell tumors specimens Builds upon Predictive's biomarker discovery platform to select targeted patient cohorts to significantly de-risk clinical trials PITTSBURGH, April 15, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery, announced today that it has made significant progress along the continuum of biomarker discovery, drug discovery and drug repurposing. These latest developments build upon Predictive's ongoing initiative to combine its in-house biomarker identification platform with its AI screening capabilit
LOS ANGELES, April 04, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ:RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today provided an update regarding its Definitive Agreement with Predictive Oncology Predictive Oncology, Inc. (NASDAQ:POAI) to initiate the previously announced integration of AI/ML platform technologies, core laboratory capabilities and business development efforts in Europe and the United States. Renovaro entered into a binding agreement merger agreement with Predictive Oncology, Inc. ("POI") dated January 1, 2025, and supplemented with the Extension Agreement dated February 28, 2025
PITTSBURGH, April 01, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended December 31, 2024, and provided a corporate update. The Company reported a loss from continuing operations of approximately $10.8 million on total revenue of $1.6 million for the year ended December 31, 2024. On January 6, 2025, Predictive Oncology announced that it has entered into an agreement to merg
AIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and common diseases, today announced the appointment of Matthew Hawryluk, Ph.D., MBA, as Chief Business Officer. Dr. Hawryluk brings vast leadership experience in the life sciences sector, with a proven track record of bridging scientific innovation and commercial application. "Matt is a tremendous addition to our leadership team, bringing extensive experience driving collaborations and leading high-performing teams," said Kris Elverum, President and CEO of AIRNA. "Matt joins us at a critical time, as we prepare to bring our first RNA editing therapeutic to the clinic. We have the pote
Company to Host International Roadshow the Week of January 13, 2025 LOS ANGELES, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today issued a letter to shareholders from Chief Executive Officer David Weinstein. Dear Shareholders, As we enter the new year, I wanted to update you on the progress we have made in the last two months and further define our trajectory for 2025. Our comprehensive analysis of both businesses and development of a 100-day plan of action has already turned up some hidden value in both businesses and is helping us understand key areas of the business we need to for
EAGAN, Minn., June 27, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced the appointment of biopharmaceutical finance veteran Mr. Andrew Einhorn to its Business Advisory Board. "Andrew Einhorn brings a wealth of senior financial leadership experience in the biopharmaceutical industry to our Business Advisory Board, and I am very pleas
424B5 - Predictive Oncology Inc. (0001446159) (Filer)
8-K/A - Predictive Oncology Inc. (0001446159) (Filer)
8-K - Predictive Oncology Inc. (0001446159) (Filer)
PITTSBURGH, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended September 30, 2024, and provided a corporate update. The Company reported a loss from continuing operations of approximately $2.3 million on total revenue of $345,686 for the quarter. Predictive Oncology also announced today that the company's Board of Directors, working with a strategic advisor, has i
PITTSBURGH, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended June 30, 2024, and provided a corporate update. The Company reported a net loss of approximately $3.2 million on total revenue of approximately $0.3 million for the quarter. Q2 2024 and Recent Highlights: Entered biomarker discovery market following compelling results from retrospective ovarian cancer s
PITTSBURGH, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced that it will report its financial results for the second quarter ended June 30, 2024 before the markets open on Wednesday, August 14, 2024. The company will host a corporate update conference call and live audio webcast at 8:30 a.m. ET. Live Conference Call & Webcas
SC 13G/A - Predictive Oncology Inc. (0001446159) (Subject)
SC 13G - Predictive Oncology Inc. (0001446159) (Subject)
H.C. Wainwright initiated coverage of Predictive Oncology with a rating of Buy and set a new price target of $3.00
HC Wainwright & Co. initiated coverage of Predictive Oncology with a rating of Buy and set a new price target of $5.00
Litchfield Hills Research initiated coverage of Predictive Oncology with a rating of Buy and set a new price target of $3.00
4 - Predictive Oncology Inc. (0001446159) (Issuer)
4 - Predictive Oncology Inc. (0001446159) (Issuer)
4 - Predictive Oncology Inc. (0001446159) (Issuer)